{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:02:09Z","timestamp":1780718529428,"version":"3.54.1"},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.2169\/internalmedicine.6290-25","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T22:08:40Z","timestamp":1760566120000},"page":"1514-1519","source":"Crossref","is-referenced-by-count":2,"title":["Drug-induced Interstitial Lung Disease with a Hypersensitivity Pneumonitis Pattern Following Pembrolizumab Plus Epirubicin and Cyclophosphamide Therapy: First Report with Pathological Findings"],"prefix":"10.2169","volume":"65","author":[{"given":"Shota","family":"Kaburaki","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kamio","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Terasaki","sequence":"additional","affiliation":[{"name":"Department of Analytic Human Pathology, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Blohmer JU, Schmid P, Hilfrich J, et al. Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial. Ann Oncol 21: 1430-1435, 2010.","DOI":"10.1093\/annonc\/mdp585"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Langley RE, Carmichael J, Jones AL, et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol 23: 8322-8330, 2005.","DOI":"10.1200\/JCO.2005.01.1817"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Untch M, von Minckwitz G, Konecny GE, et al.; Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer - outcome on prognosis. Ann Oncol 22: 1999-2006, 2011.","DOI":"10.1093\/annonc\/mdq713"},{"key":"4","unstructured":"4. Omoto H, Takada M, Fujii S, Ito H, Yamashita S. A case of drug-induced interstitial lung disease associated with epirubicin and cyclophosphamide therapy before operation. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 46: 160-162, 2019."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Egashira A, Yanagihara T, Ogo N, Asoh T, Maeyama T. A case of drug-induced interstitial lung disease caused by epirubicin and cyclophosphamide therapy before breast cancer surgery. Cureus 13: e20676, 2021.","DOI":"10.7759\/cureus.20676"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hoshina H, Takei H. Drug-induced interstitial lung disease after anthracycline-combined chemotherapy for breast cancer: a case report and literature review. Case Rep Oncol 14: 1671-1676, 2021.","DOI":"10.1159\/000520126"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Schmid P, Cortes J, Dent R, et al.; the KEYNOTE-522 investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 386: 556-567, 2022.","DOI":"10.1056\/NEJMoa2112651"},{"key":"8","unstructured":"8. Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 202: e36-e69, 2020."},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Fern\u00e1ndez P\u00e9rez ER, Travis WD, Lynch DA, et al. Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest 160: e97-e156, 2021.","DOI":"10.1016\/j.chest.2021.03.066"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Guillon JM, Joly P, Autran B, et al. Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann Intern Med 117: 476-481, 1992.","DOI":"10.7326\/0003-4819-117-6-476"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tamura M, Saraya T, Fujiwara M, et al. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist 18: 454-459, 2013.","DOI":"10.1634\/theoncologist.2012-0248"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lee IH, Kang GW, Kim KC. Hypersensitivity pneumonitis associated with azathioprine therapy in a patient with granulomatosis with polyangiitis. Rheumatol Int 36: 1027-1032, 2016.","DOI":"10.1007\/s00296-016-3489-0"},{"key":"13","unstructured":"13. Martin N, Innes JA, Lambert CM, Turnbull CM, Wallace WAH. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol 34: 1934-1937, 2007."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Salehi M, Miller R, Khaing M. Methotrexate-induced Hypersensitivity Pneumonitis appearing after 30 years of use: a case report. J Med Case Rep 11: 174, 2017.","DOI":"10.1186\/s13256-017-1333-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kallel F, Kassar O, Maaloul I, Charfi M, Ksouda K, Elloumi M. Hypersensitivity pneumonitis related to imatinib mesylate therapy in a patient with chronic myeloid leukemia. J Oncol Pharm Pract 27: 1762-1765, 2021.","DOI":"10.1177\/1078155220984239"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bergeron A, Bergot E, Vilela G, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol 20: 4271-4272, 2002.","DOI":"10.1200\/JCO.2002.99.179"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sandhu HS, Barnes PJ, Hernandez P. Hydroxyurea-induced hypersensitivity pneumonitis: a case report and literature review. Can Respir J 7: 491-495, 2000.","DOI":"10.1155\/2000\/297045"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 50: 1700050, 2017.","DOI":"10.1183\/13993003.00050-2017"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22: 6051-6060, 2016.","DOI":"10.1158\/1078-0432.CCR-16-1320"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35: 709-717, 2017.","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Drug-induced interstitial lung disease. Eur Respir J 60: 2102776, 2022.","DOI":"10.1183\/13993003.02776-2021"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med 7: 356, 2018.","DOI":"10.3390\/jcm7100356"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Pichler WJ. The p-i concept: pharmacological interaction of drugs with immune receptors. World Allergy Organ J 1: 96-102, 2008.","DOI":"10.1097\/WOX.0b013e3181778282"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229, 2004.","DOI":"10.1124\/pr.56.2.6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202: 1691-1701, 2005.","DOI":"10.1084\/jem.20050915"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol 23: 487-500, 2022.","DOI":"10.1038\/s41590-022-01132-2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 154 (Pt 1): 1851-1856, 1996.","DOI":"10.1164\/ajrccm.154.6.8970380"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20: 1245-1259, 2000.","DOI":"10.1148\/radiographics.20.5.g00se081245"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Schwaiblmair M, Behr W, Foerg W, Berghaus T. Cytochrome P450 polymorphisms and drug-induced interstitial lung disease. Expert Opin Drug Metab Toxicol 7: 1547-1560, 2011.","DOI":"10.1517\/17425255.2011.629185"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_6290-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:31:28Z","timestamp":1780716688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_6290-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6290-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"6290-25"}}